Literature DB >> 3118763

A rating scale for amyotrophic lateral sclerosis: description and preliminary experience.

V Appel1, S S Stewart, G Smith, S H Appel.   

Abstract

A rating scale has been developed to provide a quantitative estimate of clinical status and disease progression in amyotrophic lateral sclerosis (ALS). This scale includes assessment of swallowing, speech, and respiratory function, and both strength and function of upper and lower extremity musculature. The evaluation is relatively simple to perform and yields reproducible data for both a total ALS score and a score for each group of functions tested. A score of 30 points is normal; 164 points indicates maximal dysfunction. The total ALS score increased in a linear fashion in each of 74 patients followed for at least one year. Among patients, the rate of disease progression varied twenty-fold, with a continuous distribution from the slowest to most rapid course. Thirty-four percent of patients exhibited a rapid change of greater than 48 points in the year, predicting progression to a terminal stage in less than two years; 19% of patients exhibited a slow change of less than 13 points in one year, predicting progression to a terminal stage over at least five years. This ALS scoring system should permit more accurate assessment of drug efficacy in clinical trials and correlation of rates of progression with clinical variables.

Entities:  

Mesh:

Year:  1987        PMID: 3118763     DOI: 10.1002/ana.410220308

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  29 in total

Review 1.  Molecular mechanisms regulating motor neuron development and degeneration.

Authors:  T J Kilpatrick; M Soilu-Hänninen
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

2.  Disorders of Sleep and Breathing during Sleep in Neuromuscular Disease.

Authors:  Erik Van Lunteren; Henry J. Kaminski
Journal:  Sleep Breath       Date:  1999       Impact factor: 2.816

3.  Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis.

Authors:  P J Massman; J Sims; N Cooke; L J Haverkamp; V Appel; S H Appel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

Review 4.  Measures and markers in amyotrophic lateral sclerosis.

Authors:  Merit Cudkowicz; Muhammad Qureshi; Jeremy Shefner
Journal:  NeuroRx       Date:  2004-04

Review 5.  Amyotrophic lateral sclerosis: current and future treatment strategies.

Authors:  B W Festoff
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 6.  Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis.

Authors:  Seward B Rutkove
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

7.  Facioscapulohumeral muscular dystrophy: a prospective study of weakness and functional impairment.

Authors:  Joerg-Patrick Stübgen; Annette Stipp
Journal:  J Neurol       Date:  2010-03-30       Impact factor: 4.849

8.  Amyotrophic lateral sclerosis: early predictors of prolonged survival.

Authors:  Adam Czaplinski; Albert A Yen; Stanley H Appel
Journal:  J Neurol       Date:  2006-06-13       Impact factor: 4.849

9.  Continuous response variable trial design in motor neuron disease: long term treatment with a TRH analogue (RX77368).

Authors:  A Goonetilleke; R J Guiloff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

10.  Progression in primary lateral sclerosis: a prospective analysis.

Authors:  Mary Kay Floeter; Reversa Mills
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.